1.Surgeon's View of Chemotherapy in Gastric Cancer.
Journal of the Korean Gastric Cancer Association 2003;3(4):166-171
No abstract available.
Drug Therapy*
;
Stomach Neoplasms*
2.Intraperitoneal Chemotherapy for Gastric Cancer.
Journal of the Korean Gastric Cancer Association 2002;2(1):1-4
No abstract available.
Drug Therapy*
;
Stomach Neoplasms*
3.Advanced colorectal cancer: Do we need chemotherapy?.
Korean Journal of Medicine 1999;57(4):732-736
No abstract available.
Colorectal Neoplasms*
;
Drug Therapy*
4.The hematologic toxicity of MFC chemotherapy following surgery for gastric cancer.
Hyo Cheol PARK ; Jae Hong KIM ; Ju Sup PARK
Journal of the Korean Surgical Society 1992;42(2):171-178
No abstract available.
Drug Therapy*
;
Stomach Neoplasms*
5.Efficacy of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.
The Korean Journal of Gastroenterology 2016;68(5):234-236
No abstract available.
Drug Therapy*
;
Stomach Neoplasms*
6.The prognostic value of serial measurement of serum CA-125 levels during chemotherapy of epithelial ovarian cancer.
Soon Beom KANG ; Hye Sung MOON ; Seung Kew BAIK ; Byung Gi KIM ; Yong Sang SONG ; Hyo Pyo LEE
Korean Journal of Obstetrics and Gynecology 1993;36(11):3750-3760
No abstract available.
Drug Therapy*
;
Ovarian Neoplasms*
7.Chemotherapy of Gastric Cancer.
Korean Journal of Medicine 1998;55(4):496-502
No abstract available.
Drug Therapy*
;
Stomach Neoplasms*
8.Chemotherapy of Gastric Cancer.
Korean Journal of Medicine 1998;55(4):496-502
No abstract available.
Drug Therapy*
;
Stomach Neoplasms*
9.Recent advances in systemic chemotherapy for metastatic colorectal cancer.
Korean Journal of Medicine 2004;67(4):330-340
No abstract available.
Colorectal Neoplasms*
;
Drug Therapy*
10.Establishing the draft for studying the roles of chemotherapy, immunotherapy and herb (Panax pseudo-ginseng) for some intestinal carcinomas (gastric, hepatic and pancreatic carcinoma) in the Intestinal Surgical Department of ViÖt §øc Hospital
Journal of Practical Medicine 1998;351(6):35-37
The minimal condition for chemotherapy is the malignant nature of tumor must be identified exactly, the clinical criteria must be established adequately and accurately, contraindications should be excluded, the following-up factors were enough and the cooperation of patients should be available. In this clinical trial, patients were divided randomly into 3 groups. Group 1 received surgery alone. Group 2 received surgery plus 5FU. Groups 3 received surgery plus 5FU and false ginseng. Result: The 5-year survival rate increased more than 15% for groups received post-operative adjunctive therapy. The 5-year survival in adjunctive therapy groups is 45%.
Immunotherapy
;
Drug Therapy
;
neoplasms
Result Analysis
Print
Save
E-mail